NASDAQ:NKTX - Nkarta Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.00
  • Forecasted Upside: 25.69 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$46.94
▼ -1.6 (-3.30%)
1 month | 3 months | 12 months
Get New Nkarta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$59.00
▲ +25.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $59.00, with a high forecast of $81.00 and a low forecast of $41.00. The average price target represents a 25.69% upside from the last price of $46.94.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Nkarta.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/23/2020MizuhoBoost Price TargetBuy$47.00 ➝ $81.00N/A
i
12/7/2020MizuhoBoost Price TargetBuy$34.00 ➝ $47.00High
i
8/4/2020Evercore ISIInitiated CoverageOutperform$55.00High
i
8/4/2020Stifel NicolausInitiated CoverageBuy$41.00High
i
8/4/2020MizuhoInitiated CoverageBuy$34.00High
i
8/4/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 3/3/2016 forward)
Nkarta logo
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $46.94
$45.81
$49.21

50 Day Range

MA: $49.98
$37.56
$56.93

52 Week Range

Now: $46.94
$22.46
$79.16

Volume

158,501 shs

Average Volume

212,820 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Nkarta?

The following Wall Street research analysts have issued research reports on Nkarta in the last year: Cowen Inc, Evercore ISI, Mizuho, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for NKTX.

What is the current price target for Nkarta?

3 Wall Street analysts have set twelve-month price targets for Nkarta in the last year. Their average twelve-month price target is $59.00, suggesting a possible upside of 21.5%. Mizuho has the highest price target set, predicting NKTX will reach $81.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $41.00 for Nkarta in the next year.
View the latest price targets for NKTX.

What is the current consensus analyst rating for Nkarta?

Nkarta currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTX will outperform the market and that investors should add to their positions of Nkarta.
View the latest ratings for NKTX.

What other companies compete with Nkarta?

How do I contact Nkarta's investor relations team?

Nkarta's physical mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-215-0385 and its investor relations email address is [email protected] The official website for Nkarta is www.nkartatx.com.